NJ State Employees Deferred Compensation Plan’s Madrigal Pharmaceuticals MDGL Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,500	Closed	-$688K	–	242
2025 Q3	$688K	Hold	1,500	–	–	0.08%	244
2025 Q2	$454K	Hold	1,500	–	–	0.05%	294
2025 Q1	$497K	Hold	1,500	–	–	0.06%	268
2024 Q4	$463K	Hold	1,500	–	–	0.06%	307
2024 Q3	$318K	Hold	1,500	–	–	0.04%	363
2024 Q2	$420K	Hold	1,500	–	–	0.05%	315
2024 Q1	$401K	Hold	1,500	–	–	0.05%	327
2023 Q4	$347K	Hold	1,500	–	–	0.05%	353
2023 Q3	$219K	Hold	1,500	–	–	0.03%	412
2023 Q2	$347K	Hold	1,500	–	–	0.05%	346
2023 Q1	$363K	Buy	+1,500	New	+$409K	0.06%	343

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's MDGL Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 1,500 shares — an estimated $688K sold.

NJ State Employees Deferred Compensation Plan first reported a position in MDGL in Q1 2023 and held it in 11 quarters. The position peaked at $688K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 1,500 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $688K.
NJ State Employees Deferred Compensation Plan first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 11 quarters.
NJ State Employees Deferred Compensation Plan's Madrigal Pharmaceuticals position peaked at $688K in Q3 2025.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.